What is new in topical therapy for psoriasis?

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue SUPPL. 4, 2011, Pages 15-20

  Reich, K ^a   Bewley, A ^b  

^a Dermatologikum Hamburg   (Germany)

^b WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CORTISONE ACETATE PLUS NEOMYCIN; DRUG VEHICLE; VITAMIN D;

DATA ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURED INTERVIEW; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS;

EID: 79955404842     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04061.x     Document Type: Review

References (21)

1. Schön MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-1912. (Pubitemid 40627816)
2. Feldman SR, Horn EJ, Balkrishnan R, et al. International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008; 59: 1009-1016.
3. Hol K,. Patient preference for topical psoriasis formulations. Abstract presented at the European Academy of Dermatology and Venerology congress, 6-10 Oct 2010, Gothenburg, Sweden. P572.
4. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV,. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31-36. (Pubitemid 28327834)
5. Brown KK, Rehmus WE, Kimball AB,. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-613. (Pubitemid 44436629)
6. Fouéré S, Adjadj L, Pawin H,. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 3): 2-6. (Pubitemid 41726918)
7. Vakirlis E, Kastanis A, Ioannides D,. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag 2008; 4: 141-148. (Pubitemid 351460940)
8. O'Neill JL, Feldman SR,. Vitamin D analogue-based therapies for psoriasis. Drugs Today (Barc) 2010; 46: 351-360.
9. Menter A, Griffiths C,. Current and future management of psoriasis. Lancet 2007; 370: 272-284. (Pubitemid 47071926)
10. Douglas W, Poulin Y, Decroix JP, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venerol 2002; 82: 131-135. (Pubitemid 34596689)
11. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
12. Kaufmann R, Bibby A, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet®) is an effective treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393. (Pubitemid 35356768)
13. Kragballe K, Noerrelund K, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-1173. (Pubitemid 38932288)
14. Papp K, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54. (Pubitemid 36091533)
15. Ortonne JP, Kaufmann R, Lecha M, Goodfield M,. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised double-blind trial. Dermatology 2004; 209: 308-313. (Pubitemid 39482622)
16. Claréus BW, Houwing R, Sindrup JH, Wigchert S,. The DESIRE study-psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009; 19: 1-5.
17. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr,. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9: 2.
18. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160. (Pubitemid 43727399)
19. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-471.
20. Langley R, Gupta A, Papp K, Wexler D, Curcic D,. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011; Feb 3 (Epub ahead of print).
21. Hol K,. European study into the opinions of psoriasis patients and physicians. Abstract presented at the European Academy of Dermatology and Venerology congress, 6-10 Oct 2010, Gothenburg, Sweden. P573.